Effects of 5-bromotetrandrine and daunorubicin on apoptosis and expression of survivin in K562/A02 cells / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 24-27, 2011.
Article
Dans Zh
| WPRIM
| ID: wpr-332293
Responsable en Bibliothèque :
WPRO
ABSTRACT
The aim of this study was to investigate the potential benefit of combination therapy with 5-bromotetrandrine (5-BrTet) and daunorubicin (DNR) on chronic leukemia. The apoptosis of K562/A02 cells treated by DNA, BrTet and BrTet combined with DNR for 48 hours was detected by flow cytometry; the expressions levels of survivin mRNA and protein K562/A02 cells treated by DNR, BrTet and BrTet combined with DNR and in untreated K562 cells for 48 hours were measured by RT-PCR and Western blot respectively. The results showed that the combination of BrTet with DNR increased apoptotic rate of K562/A02, down-regulated the expression levels of survivin mRNA and protein in K562/A02 cells as compared with blank control and cells treated by BrTet or DNR alone, the survivin expression in K562/A02 cells was higher than that in K562 cells. It is concluded that the combination of BrTet with DNR can effectively reverse the multidrug resistance of K562/A02 cells, promote the apoptosis of K562/A02 cells, the mechanism of which may be related with down-regulation of survivin expression. Survivin may be a target for the treatment of MDR in hematopoietic malignancies.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pharmacologie
/
Daunorubicine
/
Régulation de l'expression des gènes dans la leucémie
/
Apoptose
/
Multirésistance aux médicaments
/
Résistance aux médicaments antinéoplasiques
/
Cellules K562
/
Benzylisoquinoléines
/
Protéines IAP
/
Génétique
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Journal of Experimental Hematology
Année:
2011
Type:
Article